Latest News

Publications

Cell_A-selective-antibiotic-for-Lyme-disease

October 6, 2021

A selective antibiotic for Lyme disease

Nadja Leimer, Xiaoqian Wu, Yu Imai, Linden T. Hu, Helen I. Zgurskaya, Kim Lewis
mBio-2020-Morrissette-e02310-20.full_

October 1, 2020

A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients

Madeleine Morrissette, Norman Pitt, Antonio González, Philip Strandwitz, Mariaelena Caboni, Alison W. Rebman, Rob Knight, Anthony D’Onofrio, John N. Aucott, Mark J. Soloski, Kim Lewis
s41598-020-59600-4

March 2, 2020

Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31

Venkata Raveendra Pothineni, Hari-Hara S. K. Potula, Aditya Ambati, Venkata Vamsee Aditya Mallajosyula, Brindha Sridharan, Mohammed Inayathullah, Mohamed Sohail Ahmed, and Jayakumar Rajadas
liegner

May 30, 2019

Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases

By Kenneth Liegner
shor

December 16, 2019

Chronic Lyme Disease: An Evidence-Based Definition by the ILADS Working Group

By Samuel Shor, Christine Green, Beatrice Szantyr, Steven Philips, Kenneth Liegner, Joseph Burrascano Jr., Robert Bransfield, Elizabeth L. Maloney
barth

November 16, 2009

Ineffectiveness of tigecycline against persistent Borrelia burgdorferi

By Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ
06-29-2022

PA Legislation: Combats Long Term Effects of Lyme & Other TBD’s

06-28-2022

A New Look at Chronic Lyme by Pamela Weintraub

06-27-2022

Valneva & Pfizer Take Next Steps in Progressing Lyme Disease Vaccine Candidate VLA15

06-23-2022

Adverse Childhood Events, PTSD, Infectious Encephalopathies and Immune-Mediated Disease

06-21-2022

Relapsing Babesiosis Case Treated Successfully with Tafenoquine

06-16-2022

Analysis Shows Nearly 15% of the Global Population Likely Has Lyme Disease